Summary of Reddit Comments on Nuvectis Pharma

• NVCT is projected to increase in value significantly.
• The news of NXP900 showing synergy with ALK inhibitors in resistant NSCLC cells is seen as a major breakthrough in lung cancer treatment.
• Management's ownership of 35% of shares indicates a strong commitment to the company's success.
• The company has shown controlled cash burn, with $17.2M still in the bank providing a runway into 2026.
• Utilizing ATM to maintain funding levels is considered a smart strategy.
• The upcoming NXP800 data in platinum-resistant ovarian cancer, with Fast Track and Orphan Drug designations, is anticipated to be a significant catalyst for the company's growth.
• The potential success of the NXP800 data could lead to a market cap increase similar to Nuvalent's trajectory.
• Nuvectis Pharma has no debt, a solid pipeline targeting major unmet needs, and strong insider alignment, establishing it as a promising biotech company.